Gastroesophageal reflux disease and erosive esophagitis
Clinical activity is centered on GERD and erosive esophagitis, with emphasis on healing, maintenance of healing, and symptom-related disease control in patients with reflux-related mucosal injury.
- Erosive gastroesophageal reflux disease
- Erosive esophagitis due to GERD
- Healing of reflux-associated esophageal lesions
- Maintenance of mucosal healing
The sponsor’s research in this area reflects a strong focus on upper gastrointestinal disorders managed through acid suppression and mucosal protection.
Helicobacter pylori infection
Another area of interest is Helicobacter pylori infection, covering an infectious cause of upper gastrointestinal disease that is closely linked to peptic and gastric pathology.
- Helicobacter pylori
- Upper gastrointestinal infection
- Gastric disease associated with bacterial colonization
This adds an infectious disease dimension to the sponsor’s broader gastrointestinal portfolio.
Acid-related gastrointestinal therapeutics
The funded studies are closely aligned with therapies targeting gastric acid suppression, reflecting interest in treatment options for reflux-mediated injury and related acid-dependent conditions.
- Acid suppression
- Upper gastrointestinal mucosal healing
- Reflux-related disease management
These programs place the sponsor within the therapeutic landscape of gastroenterology and acid-related disorders.
Clinical pharmacology and safety assessment
The portfolio also includes early clinical evaluation of gastrointestinal candidates, with attention to pharmacokinetics and cardiac electrophysiology in healthy participants.
- Pharmacokinetics
- ECG effects
- Healthy participant studies
- Drug interaction assessment
These topics support the clinical development of therapies intended for gastrointestinal disease treatment.
